Former Supervalu, Target executive dies at 56
MINNEAPOLIS Esteemed retail executive Paul Singer — whose career included serving as SVP and chief information officer for both Target and Supervalu — died last week after a 19-month battle with brain cancer. He was 56.
Singer’s death was first reported by the Minneapolis-St. Paul Business Journal. Singer most recently served as Supervalu’s CIO and SVP from July 2006 until last year. The company cited his deteriorating health for his departure. In his role at the supermarket chain, he “successfully merged two IT organizations into one [and] expanded the company’s global reach by establishing Supervalu India,” current Supervalu CIO Wayne Shurts wrote in a memo posted by Storefrontbacktalk.com.
Singer also had a more than two-decade career at Target, where he started as a business analyst and eventually became the company’s SVP and CIO. He retired from his post in 2005 to join Supervalu, the Journal said.
Singer is survived by his wife of 35 years, Teri; children Lisa (Aaron) Martin, Rachel, Natasha, Svetlana and Angela; grandchildren Blake, Sophie and Alison; mother, Jessie Mae Singer; sister, Patricia (Roy) Hulehan; brother, Ray Singer; and nephews.
‘Battle of the bulge’ solved with Perfect Fit Button
FAIRFIELD, N.J. Need a quick fix for pants that just don’t fit right? Look no further than the Perfect Fit Button, an innovative new product that helps prolong the comfortable fit of pants, jeans or skirts by creating an easy way to adjust the waistband.
Made by TeleBrands, the company behind such products as storage solution Shoes Under and PedEgg, the Perfect Fit Button is the newest way to get pants and skirts to fit without having to spend extra money. It retails for $9.99 for a set of eight.
Patient enrollment complete for lung cancer treatment trial
SOUTH SAN FRANCISCO, Calif. Drug maker OXiGENE has finished enrolling patients for a mid-stage clinical trial of a lung cancer treatment, the company said Wednesday.
OXiGENE announced that it had enrolled 60 patients in “FALCON,” a phase 2 trial of the drug Zybrestat, a treatment for non-small cell lung cancer. The trial comprises two arms, a study arm with patients taking Zybrestat with Genentech’s Avastin (bevacizumab) and chemotherapy, and a control arm with patients taking Avastin and chemotherapy alone. OXiGENE said some preliminary results from the trial presented at the recent meeting of the American Society of Clinical Oncology have indicated that the drug is safe and effective.
“We look forward to presenting a more complete analysis of the FALCON trial later in 2010 at a scientific meeting,” OXiGENE CEO Peter Langecker said. “If the encouraging positive trends in terms of progression-free survival and overall survival that we presented at ASCO are maintained, they will underscore Zybrestat’s utility in non-small cell lung cancer and potentially pave the way toward embarking upon a registration pathway.”